# reload+after+2024-01-21 04:45:56.476327
address1§377 Plantation Street
address2§1st floor
city§Worcester
state§MA
zip§01605
country§United States
phone§781 652 4500
website§https://www.mustangbio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
fullTimeEmployees§113
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Michael S. Weiss Esq.', 'age': 57, 'title': 'Executive Chairman', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 60000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Manuel  Litchman M.D.', 'age': 69, 'title': 'President, CEO, Interim CFO & Director', 'yearBorn': 1954, 'fiscalYear': 2022, 'totalPay': 618852, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Peter  Carney', 'age': 37, 'title': 'Controller & Interim Chief Accounting Officer', 'yearBorn': 1986, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Matthew  Wein J.D.', 'title': 'VP & General Counsel', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Debra  Manning SPHR', 'title': 'Senior VP & Head of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Lynn E. Bayless M.S.', 'title': 'VP & Head of Regulatory Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Bruce  Dezube M.D.', 'title': 'Senior VP & Head of Clinical Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Greg  Furrow M.S.', 'title': 'Chief Quality Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Richard  Bodmer M.S.', 'title': 'Head of CMC Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Robert  Sexton M.B.A., M.S.', 'title': 'VP and Head of Program & Alliance Leadership', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.709
currency§USD
dateShortInterest§1702598400
forwardEps§-2.38
exchange§NCM
quoteType§EQUITY
shortName§Mustang Bio, Inc.
longName§Mustang Bio, Inc.
firstTradeDateEpochUtc§1503408600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§15a28276-d177-3bd2-8aa8-03ffce90d2d7
gmtOffSetMilliseconds§-18000000
targetHighPrice§25.0
targetLowPrice§8.0
targetMeanPrice§14.33
targetMedianPrice§10.0
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§3
quickRatio§0.675
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
